Back to News
Market Impact: 0.12

Touchstone Small Cap Fund Q3 2025 Contributors And Detractors

AWINGVTGHCHAEWTM
Corporate EarningsCompany FundamentalsInvestor Sentiment & PositioningHealthcare & BiotechManagement & GovernanceMarket Technicals & Flows
Touchstone Small Cap Fund Q3 2025 Contributors And Detractors

Touchstone Fund performance was led by holdings including Armstrong World Industries, Ingevity and Graham Holdings, with Graham outperforming on strong Q2 results driven by Kaplan Education growth and expansion in its Healthcare segment. Key detractors included Interparfums, Haemonetics and White Mountains Insurance Group, the latter weighed by industry headwinds and portfolio investment volatility; Touchstone reiterates its "Distinctively Active" manager selection and portfolio-construction approach.

Analysis

Market structure: Winners are Graham Holdings (GHC) and cyclical/industrial exposures like Armstrong World (AWI) and Ingevity (NGVT) — GHC’s Kaplan/Healthcare mix increases recurring revenue and raises short-to-mid term cashflow visibility; losers are balance-sheet sensitive insurers like White Mountains (WTM) and procedural/consumables names such as Haemonetics (HAE) where investment volatility and elective-procedure weakness compress returns. Competitive dynamics shift modest share to diversified services (education/healthcare) versus pure insurtech/insurance holdings, and specialty chemicals sustain pricing power if industrial activity stays within +/-5% of current run-rates. Risk assessment: Tail risks include a >15% equity drawdown that would force further markdowns at WTM, a regulatory shock to for-profit education or healthcare reimbursement changes that could cut GHC margins by 200–500bp, and a >20% oil move that compresses NGVT margins. Time horizons: immediate (days) = volatility spikes around earnings; short-term (weeks–months) = portfolio rebalancing and mark-to-market pressure for insurers; long-term (quarters–years) = secular enrollment trends for Kaplan and industrial capex cycles for AWI/NGVT. Hidden dependency: WTM’s performance is driven more by investment portfolio beta than underwriting trends; catalysts include next 60-day CPI, 10y US yield moves, and Q3 earnings from GHC/AWI/NGVT. Trade implications: Favor tactical longs in GHC (1–3% portfolio weight) and selective AWI/NGVT exposure (0.5–2% each) funded by trimming insurance holdings (WTM) and HAE. Relative-value: long GHC vs short WTM to capture earnings/valuation divergence; options: buy 3–6 month GHC calls (delta ~0.35) and buy 3–6 month puts on WTM (10–15% OTM) to asymmetrically express views. Enter within 2–6 weeks ahead of next corporate updates, target 20–30% upside exits, use 12–15% stop-loss or options hedge to cap downside. Contrarian angles: Consensus underweights Kaplan’s secular reskilling demand — if enrollment growth sustains +5–10% YoY, GHC upside is underappreciated. HAE’s weakness may be overstated given elective procedure normalization; a 3–6 month recovery could flip short positions. Conversely, shorting WTM is risky if markets stabilize and yields fall (insurance recovery); historical parallels (post-2016 insurance rebound) warn against large, unhedged shorts. Manage crowding: size shorts no more than 1–1.5% net exposure and pair with long volatility or equity hedges.